Please use this identifier to cite or link to this item:
http://acervodigital.unesp.br/handle/11449/65759
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Carvalho, Maria Fernanda C. | - |
dc.contributor.author | Viero, Rosa Marlene | - |
dc.contributor.author | Soares, Vitor A. | - |
dc.date.accessioned | 2014-05-27T11:19:43Z | - |
dc.date.accessioned | 2016-10-25T18:15:41Z | - |
dc.date.available | 2014-05-27T11:19:43Z | - |
dc.date.available | 2016-10-25T18:15:41Z | - |
dc.date.issued | 1999-04-06 | - |
dc.identifier | http://dx.doi.org/10.3109/08860229909066979 | - |
dc.identifier.citation | Renal Failure, v. 21, n. 2, p. 147-154, 1999. | - |
dc.identifier.issn | 0886-022X | - |
dc.identifier.uri | http://hdl.handle.net/11449/65759 | - |
dc.identifier.uri | http://acervodigital.unesp.br/handle/11449/65759 | - |
dc.description.abstract | The role of superoxide in adriamycin-induced nephropathy (single dose; i.v. 3 mg/kg) has been studied by blocking superoxide synthesis through the administration of allopurinol (500 mg/L in drinking water). In Experiment I (EI), allopurinol administration was started 3 days prior to nephropathy induction and continued until day 14. In Experiment II (EII) allopurinol administration was started 2 weeks after nephropathy induction and was maintained until the end of the experiment (26 weeks). Affected glomeruli frequency and tubulointerstitial lesion index (TILI) were determined at Weeks 2 and 4 (EI) and Week 26 (EII). In EI, and 24 h mean proteinuria in the nephrotic control group (NCG-I) differed from that of the treated nephrotic group (TNG-I) at Week 1 (TNG = 33.3 ± 6.39 mg/24 h; NCG = 59.8 ± 6.3 mg/24 h; p < 0.05) and 2 (NCG-I = 80.0 ± 17.5 mg/24h; TNG-I = 49.1 ± 8.4 mg/24 h; p < 0.05). No glomerular alterations were observed and TILI medians were not different in both nephrotic groups at week 2 (NCG-I = 1+: TNG = 1+) and 4 (NCG = 4+; TNG = 4+). In EII, NCG-II and TNG-II presented different 24 h proteinuria values only at Week 6, (136.91 ± 22.23 mg/24 h ad 72.66 ± 10.72 mg/24 h, respectively; p < 0.05). Between nephrotic groups, there was no statistical difference in the median of affected glomeruli (CNG-II = 56%; TNG-II = 48% and TILI (NCG-II = 8+; TNG-II = 9+). Thus, allopurinol was associated with a transient reduction in proteinuria and it did not alter the progression of the nephropathy. | en |
dc.format.extent | 147-154 | - |
dc.language.iso | eng | - |
dc.source | Scopus | - |
dc.subject | Adriamycin nephropathy | - |
dc.subject | Allopurinol | - |
dc.subject | Glomerulosclerosis | - |
dc.subject | Proteinuria | - |
dc.subject | Superoxide | - |
dc.subject | allopurinol | - |
dc.subject | doxorubicin | - |
dc.subject | free radical | - |
dc.subject | superoxide | - |
dc.subject | animal model | - |
dc.subject | controlled study | - |
dc.subject | drug effect | - |
dc.subject | drug induced disease | - |
dc.subject | electron microscopy | - |
dc.subject | glomerulosclerosis | - |
dc.subject | intravenous drug administration | - |
dc.subject | kidney biopsy | - |
dc.subject | kidney disease | - |
dc.subject | nephrotoxicity | - |
dc.subject | priority journal | - |
dc.subject | proteinuria | - |
dc.subject | purine metabolism | - |
dc.subject | Antineoplastic Agents | - |
dc.subject | Biopsy | - |
dc.subject | Disease Models, Animal | - |
dc.subject | Disease Progression | - |
dc.subject | Doxorubicin | - |
dc.subject | Follow-Up Studies | - |
dc.subject | Free Radical Scavengers | - |
dc.subject | Glomerulosclerosis, Focal Segmental | - |
dc.subject | Kidney Glomerulus | - |
dc.subject | Kidney Tubules | - |
dc.subject | Nephritis, Interstitial | - |
dc.subject | Random Allocation | - |
dc.subject | Rats, Wistar | - |
dc.title | Effect of allopurinol in the course of adriamycin induced nephropathy | en |
dc.type | outro | - |
dc.contributor.institution | Universidade Estadual Paulista (UNESP) | - |
dc.description.affiliation | Department of Pathology Botucatu Medical School-UNESP, Botucatu, SP | - |
dc.description.affiliation | Departamento de Clinica Medica Faculdade de Medicina de Botucatu UNESP, P.O. Box 584, CEP: 18618-970 Botucatu, SP | - |
dc.description.affiliationUnesp | Department of Pathology Botucatu Medical School-UNESP, Botucatu, SP | - |
dc.description.affiliationUnesp | Departamento de Clinica Medica Faculdade de Medicina de Botucatu UNESP, P.O. Box 584, CEP: 18618-970 Botucatu, SP | - |
dc.identifier.doi | 10.3109/08860229909066979 | - |
dc.identifier.wos | WOS:000079149000003 | - |
dc.rights.accessRights | Acesso restrito | - |
dc.relation.ispartof | Renal Failure | - |
dc.identifier.scopus | 2-s2.0-0033003520 | - |
Appears in Collections: | Artigos, TCCs, Teses e Dissertações da Unesp |
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.